Ifosfamide-induced neurotoxicity reversal with continuous veno-venous hemodialysis. A case report

Abstract

Ifosfamide is an alkylating agent used to treat different types of malignancies including lymphomas, sarcomas and germinal cell tumors. Symptoms of ifosfamide neurotoxicity can range from mild confusion, dizziness and hallucination to overt encephalopathy. Various treatment options like methylene blue, albumin infusion and rarely hemodialysis have been used to treat ifosfamide neurotoxicity. We hereby report a case of a patient with relapsed diffuse large B cell lymphoma who received methylene blue after experiencing acute renal failure and encephalopathy due to ifosfamide with no improvement. The prompt use of hemodialysis in this case has led to reversal of both renal failure and neurotoxicity.

Keywords

Ifosfamide neurotoxicity and nephrotoxicity chemotherapy side effects hemodialysis

Get full access to this article

View all access options for this article.

References

Drings

Fritsch

. Erfahrungen mit iphosphamide in hoher Einzeldosis bei metastasierten soliden Tumoren. Verh Dtsch Ges Inn Medd 1972; 78: 166–166

Kerbusch

d Kraker

Keizer

. Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolite. Clin Pharmacokinet 2001; 40: 41–62

Goren

Wright

Pratt

. Dechlorethylation of ifosfamide and neurotoxicity. Lancet 1986; 2: 1219–1220

Meanwell

. Prediction of ifosfamide/mesna associated encephalopathy. Eur J Cancer Clin Oncol 1986; 22(7): 815–819.

Curtin

Koonings

Guitierrez

. Ifosfamide-induced neurotoxicity. Gynecol Oncol 1991; 42: 193–196.

Merimsky

Reider-Groswasser

Wigler

. Encephalopathy in ifosfamide-treated patients. Acta Neurol Scand 1992; 86: 521–525.

Dimaggio

Brown

Baile

. Hallucinations and ifosfamide-induced neurotoxicity. Cancer 1994; 73: 1509–1514.

Nicolao

Giometto

. Neurological toxicity of ifosfamide. Oncology 2003; 65 Suppl 2 11–11.

Pelgrims

De Vos

Van den Brande

. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer 2000; 82: 291–294.

10.

Alonso

. Ifosfamide encephalopathy and methylene-blue: a case report. Ann Oncol 1996; 7(6): 643–644.

11.

Meanwell

Blake

Kelly

. Prediction of ifosfamide/mesna associated encephalopathy. Eur J Cancer Clin Oncol 1986; 22: 815–819.

12.

Patel

. Methylene blue for management of ifosfamide-induced encephalopathy. Ann Pharmacother 2006; 40: 299–303.

13.

Kupfer

. Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue. Lancet 1994; 343(8900): 763–764.

14.

Sweiss

Beri

Shord

. Encephalopathy after high-dose ifosfamide. Drug Safety 2008; 31: 989–996.

15.

Kettle

. Effectiveness of exogenous albumin administration for the prevention of Ifosfamide-induced encephalopathy. Pharmacotherapy 2010; 30(8): 812–817.

16.

Latcha

Maki

Schwartz

. Ifosfamide may be safely used in patients with end stage renal disease on hemodialysis. Sarcoma 2009; 2009: 1–5.

17.

Sauer

Fuger

Blumenstein

. Modulation of cytotoxicity of cytostatic drugs by hemodialysis in vitro and in vivo. Cancer Treat Rev 1990; 17: 293–300.

18.

Fiedler

Baumann

Deschler

. Haemoperfusion combined with haemodialysis in ifosfamide intoxication. Nephrol Dial Transplant 2001; 16: 1088–1089.